All case studies

Highlights

We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.

Proactive patient retention strategy in a GLP-1 RA trial

Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.

A small biotech success story

A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.

FSP partnership - sustained efficiency and ongoing innovation

The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.

By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.

All case studies

Filter our case studies by categories, selecting amongst our broad range of solutions.

Patient recruitment & retention services

A large biopharmaceutical company with a Phase III trial enrolling 430 advanced Gastric Cancer patients contracted ICON to
support patient enrollment.

In-Home Services: Patient centric practices

Accellacare was contracted by a large pharma organisation to recruit and provide In-Home Services to paediatric patients with autism.

Agile operations drive enrollment in COVID-19 treatment studies

ICON’s Accellacare In-Home Services were used across more than 50 sites in the United States to conduct blood draws and nasal swabs, collect vital signs, and monitor for changes in health, medications, or hospitalisation for a two treatment studies in patients with COVID-19.

High-performing sites during COVID-19 in Women’s Health

A biotechnology company, dedicated to transforming Women’s Health, was running a phase 3 study in the treatment of moderate-to-severe vasomotor symptoms in postmenopausal women with a global enrollment target of 1,200 patients.

Beating patient recruitment target with enhanced patient experience

Accellacare was awarded an osteoarthritis study by a large biotech organisation. The study required recruitment of 1200+ patients across 20+ sites and four countries.

Overcoming the challenges of COVID-19 clinical trial conditions

A large biotech company contracted Accellacare to drive recruitment in a clinical trial to test the safety and
efficacy of a treatment for ambulatory patients with COVID-19. The Accellacare site in Wilmington, NC was selected for the study in August of 2020.

High performing sites in cardiovascular study

Four studies were awarded by a pharma organisation over a period of less than two years, with overlapping
start-up through close out timelines. Milestone expectations were aggressive, requiring an innovative approach and rapid start-up.

Exceeding expectations in a c. diff vaccine study

Five Accellacare sites were selected to participate in a clostridium difficile (c. diff) vaccine study being conducted
by a large pharma sponsor and ICON.

Digital solutions to reduce risk potential for six-study dermatology programme

A large pharma company conducted an extensive atopic dermatitis program consisting of six studies with complex protocols and up to 537 active sites per study. The sponsor contacted ICON to implement a centralised digital solution to better manage this massive study and reduce risk potential.

Digital solutions for an evolving COVID-19 environment

One of the top five pharmaceutical companies in the world selected ICON to initiate, manage and operate a phase 1/2/3 randomised, placebo-controlled vaccine clinical trial for SARS-CoV-2, the virus that causes COVID-19.

Optimising Biosimilar Development

ICON’s proactivity in risk mitigation, commitment to the study, project planning and communication contributed significantly to the ultimate success of the study.

CRF design for a cell-therapy, immuno-oncology study

ICON developed flexible, cost-effective CRF designs for a cell therapy immuno-oncology study, harmonising RECIST and iRECIST criteria while addressing re-treatment requirements and supporting sponsors in meeting study timelines.

Solutions case studies

Our solutions span the entire lifecycle of product development and can be adapted to suit small local trials or large global programs. Explore our work in the different aspects of our solutions.

Let's collaborate

Discover how ICON's expertise transforms clinical trials.

Blogs

Stay informed with ICON's expert insights on clinical trials, regulatory changes, and industry trends. Our blogs provide practical advice, innovative solutions, and thought leadership from global experts.

News

Stay updated with our latest news on partnerships, financial results, technological advancements, and industry insights.

Insights

Explore ICON's expert analysis and practical advice on the latest operational, regulatory, technological and economic challenges in clinical research. Our insights provide thought leadership and innovative solutions to transform trials.

Case studies

Highlights

Proactive patient retention strategy in a GLP-1 RA trial

A small biotech success story

FSP partnership - sustained efficiency and ongoing innovation

All case studies

Patient recruitment & retention services

In-Home Services: Patient centric practices

Agile operations drive enrollment in COVID-19 treatment studies

High-performing sites during COVID-19 in Women’s Health

Beating patient recruitment target with enhanced patient experience

Overcoming the challenges of COVID-19 clinical trial conditions

High performing sites in cardiovascular study

Exceeding expectations in a c. diff vaccine study

Digital solutions to reduce risk potential for six-study dermatology programme

Digital solutions for an evolving COVID-19 environment

Optimising Biosimilar Development

CRF design for a cell-therapy, immuno-oncology study

Solutions case studies

Let's collaborate

Blogs

News

Insights